OCUL - Ocular Therapeutix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.9200
+0.0400 (+0.82%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.8800
Open4.6700
Bid4.6000 x 800
Ask4.8300 x 1800
Day's Range4.6600 - 5.1850
52 Week Range2.3500 - 8.1200
Volume641,195
Avg. Volume1,010,958
Market Cap258.678M
Beta (5Y Monthly)2.06
PE Ratio (TTM)N/A
EPS (TTM)-1.9080
Earnings DateMay 07, 2020 - May 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
  • Thomson Reuters StreetEvents

    Edited Transcript of OCUL earnings conference call or presentation 12-Mar-20 8:30pm GMT

    Q4 2019 Ocular Therapeutix Inc Earnings Call

  • Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
    Zacks

    Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates

    Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -11.90% and -1.91%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Ocular Therapeutix™ Reports Fourth Quarter and Year End 2019 Financial Results and Business Update
    Business Wire

    Ocular Therapeutix™ Reports Fourth Quarter and Year End 2019 Financial Results and Business Update

    Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the fourth quarter and year ended December 31, 2019 and provided a business update.

  • ACCESSWIRE

    Ocular Therapeutix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Ocular Therapeutix, Inc. (NASDAQ:OCUL) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at ...

  • The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
    Benzinga

    The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS Medical School to develop a COVID-19 vaccine for Singapore) * Cue Biopharma Inc (NASDAQ: CUE) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Ocular Therapeutix Inc (NASDAQ: OCUL)(reacted to its preliminary fourth-quarter results and interim data from a Phase 1 study evaluating its eye implant OTX-TKI in patients with wet age-related macular degeneration) * Quest Diagnostics Inc (NYSE: DGX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN)(CEO Leonard Schleifer reportedly told CNBC the company hopes to produce COVID-19 treatment candidate that could be ready for human testing by August) * Revolution Medicines Inc (NASDAQ: RVMD) (IPOed mid-February) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX)(reacted to the company's fourth-quarter results) * Syneos Health Inc (NASDAQ: SYNH) * Viela Bio Inc (NASDAQ: VIE)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 4) * Alterity Therapeutics Ltd (NASDAQ: ATHE) * AngioDynamics, Inc. (NASDAQ: ANGO) * Aptevo Therapeutics Inc (NASDAQ: APVO) * CASI Pharmaceuticals Inc (NASDAQ: CASI) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Evogene Ltd (NASDAQ: EVGN)(reacted to fourth-quarter results) * Evolus Inc (NASDAQ: EOLS)(reacted to comments by Korean drug maker Medytox about an ITC case brought up by the company against Daewoong and partner Evolus on intellectual property related to Medytox' botulinum toxin) * Mylan NV (NASDAQ: MYL) * Orthofix Medical Inc (NASDAQ: OFIX) * Passage Bio Inc (NASDAQ: PASG)(IPOed last week) * Titan Medical Inc. (NASDAQ: TMDI)See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus Co-Diagnostics' COVID-19 Detection Kit Demand Surges Co-Diagnostics Inc (NASDAQ: CODX) said demand, both domestic and international, surged for its COVID-19 detection kits in recent weeks, leading to increased product shipments. The increase comes after the FDA changed its policy Feb. 20 and the number of cases testing positive for the disease burgeoned worldwide.The stock was surging 27.17% to $15.26 in pre-market trading.Castle Biosciences Gets First Patent For Skin Cancer Gene Expression Profile Test Skin cancer diagnostic company Castle Biosciences Inc (NASDAQ: CSTL) said the U.S. patent office has issued it the first U.S. patent related to the DecisionDx -Melanoma gene expression profile test for patients with cutaneous melanoma.FDA Accepts Trevena's Resubmitted NDA for Pain Drug Trevena Inc (NASDAQ: TRVN) said the FDA has acknowledged the receipt of and accepted the resubmitted NDA for intravenous oliceridine, its lead investigational asset, for the management of moderate-to-severe acute pain. The PDUFA date has been set for Aug. 7.In pre-market trading, shares were rising 12.35% to 91 cents.Can-Fite To Explore Treatment For COVID-19 Can-Fite BioPharma Ltd. (NASDAQ: CANF) said it is exploring a collaboration to explore if its investigational asset Piclidenoson, being evaluated for autoimmune inflammatory disease, is effective against coronavirus following reports that rheumatoid arthritis drugs have been introduced for the treatment of the same.The stock was jumping 26.28% to $1.97 in pre-market trading.RA Medical Says NYSE Accepts Plan to Regain Compliance RA Medical Systems Inc (NYSE: RMED) said the NYSE has accepted the company's business plan to regain compliance with the NYSE listing standards. Late last year, the company was notified by the NYSE regarding flouting of listing standards pertaining to average market capitalization being less than $50 million over a recent consecutive 30 days.MacroGenomics' Chief Medical Officer Resigns to Pursue Another Opportunity MacroGenics Inc (NASDAQ: MGNX) announced the resignation of Jon Wigginton as its SVP, Clinical Development & Chief Medical Officer, effective March 27, as he pursues a new opportunity. The role will be assigned on an interim basis to Ezio Bonvini, who is currently serving as SVP, Research and Chief Scientific Officer, the company said.Morphosys To Issue Additional Shares For Subscription By Incyte As Part of Tafasitamab Licensing Deal Morphosys Ag (NASDAQ: MOR) said its Management Board has resolved to increase the share capital of the company by issuing 907,441 new ordinary shares from the authorized capital to facilitate purchase of 3.63 million ADSs by Incyte Corporation (NASDAQ: INCY). The newly issued shares represent about 2.84% of the registered share capital of MorphoSys prior to the consummation of the capital increase.View more earnings on TRVNIncyte's purchase of ADSs amounting to $150 million or $41.32 per ADS is part of the consideration due to MorphoSys for the former acquiring licensing rights to develop and commercialize the latter's investigational compound tafasitamab.In pre-market trading, MorphoSys shares were slipping 3.70% to $28.89.Earnings Specialty pharma company Opiant Pharmaceuticals Inc (NASDAQ: OPNT), which develops treatment for treating addictions and drug overdose, reported fourth-quarter revenues of $7.7 million compared to $4.8 million in the fourth quarter of 2018. The company reversed to a profit of 20 cents per share from a loss of $2.49 per share last year, while analysts had estimated a loss of $2.13 per share, on average.The stock rallied 17.09% to $13.70 in after-hours trading.Offerings BridgeBio Pharma Inc (NASDAQ: BBIO) priced the upsized offering of $475 million aggregate principal amount of 2.50% convertible senior notes due 2027 in a private offering to qualified institutional buyers. The company said the notes will bear interest at a rate of 2.50% per year, payable semi-annually in arrears on March 15 and Sept. 15 of each year. Beginning Sept. 15, 2020.The company estimates to raise net proceeds of about $463.7 million from the offering.On The Radar Earnings * Arbutus Biopharma Corp (NASDAQ: ABUS) (before the market open) * BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) (before the market open) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) (before the market open) * Xtant Medical Holdings Inc (NYSE: XTNT) (before the market open) * Fulcrum Therapeutics Inc (NASDAQ: FULC) (before the market open) * Syros Pharmaceuticals Inc (NASDAQ: SYRS) (before the market open) * Obseva SA (NASDAQ: OBSV) (before the market open) * OptiNose Inc (NASDAQ: OPTN) (before the market open) * Caladrius Biosciences Inc (NASDAQ: CLBS) (after the close) * Eton Pharmaceuticals Inc (NASDAQ: ETON) (after the close) * BioNano Genomics Inc (NASDAQ: BNGO) (after the close) * Corvus Pharmaceuticals Inc (NASDAQ: CRVS) (after the close) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) (after the close)See more from Benzinga * GenMark Spikes Higher On COVID-19 Test Kit Shipment * The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More * How The COVID-19 Outbreak Is Benefiting Biotech Investors(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2019 Financial Results
    Business Wire

    Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2019 Financial Results

    Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter ended and year-ended December 31, 2019 financial results on Thursday, March 12, 2020. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Company’s financial results and provide a general business update.

  • Ocular Therapeutix™ Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial at the Cowen 40th Annual Health Care Conference
    Business Wire

    Ocular Therapeutix™ Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial at the Cowen 40th Annual Health Care Conference

    Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced preliminary unaudited net product revenue for the fourth quarter of 2019 and interim results from its Phase 1 clinical trial for OTX-TKI, a long-acting tyrosine kinase inhibitor intravitreal implant being evaluated for the treatment of wet age-related macular degeneration and other retinal diseases. A copy of the Company’s presentation from the Cowen and Company 40th Annual Health Care Conference is available on the Company’s website, www.ocutx.com.

  • Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for

    Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 3 Monster Growth Stocks Primed for Further Gains
    TipRanks

    3 Monster Growth Stocks Primed for Further Gains

    When it comes down to it, investors are focused on a single factor: a stock’s ability to deliver returns. As Wall Street observers gauge the strength of a particular investment opportunity, often, they will filter out the noise and instead, concentrate their attention on its long-term growth prospects. We are referring to whether or not a name can achieve sustainable growth over the long haul, handsomely rewarding investors in the years to come.So, with this goal in mind, what’s the first step for investors ready to get down to business? It’s narrowing down the multitude of tickers traded in the public market to a select few that represent the pick of the bunch. To make it into this exclusive group, these names should not only have strong long-term growth narratives, but also the analyst community’s support.Setting out on our own search, we used TipRanks’ Stock Screener tool to pinpoint 3 stocks that have earned “Strong Buy” consensus ratings from the analysts and boast substantial upside potential from current levels.Let’s get started.Selecta Biosciences (SELB)Selecta Biosciences believes that its ImmTOR immune tolerance platform can help patients fight rare diseases. Currently, biologic drugs can trigger neutralizing antibodies (NAbs) that work against the therapy, but ImmTOR technology allows for immune tolerance of the therapy. With this biotech already having gained 107% over the last twelve months, investors want to know if there’s more fuel left in the tank.According to Mizuho Securities analyst Difei Yang, the answer is yes. She highlights the COMPARE trial as being the driving force behind her bullish thesis. The Phase 2 clinical trial is evaluating its lead candidate, SEL-212, in patients with chronic refractory gout, specifically looking at its efficacy in resolving symptoms like flares and gouty arthritis. Based on earlier clinical data, a combined therapy of ImmTOR and pegadricase, the current uricase therapy approved by the FDA, was able to reduce the occurrence of gout flares. As a result, the data allowed SEL-212 to proceed to a head-to-head COMPARE trial, the enrollment of which was completed back in December.Yang argues that the “encouraging” interim data increases the therapy’s likelihood of FDA approval. When looking at the big picture, she is optimistic about the platform as it may lead to a re-dosing of gene therapy. Additionally, she points out that the company was able to cut its financing overhang.Given Yang’s high hopes for SELB, it makes sense that she stayed with the bulls. Not only did she maintain a Buy rating, but she also bumped up the price target from $4 to $7. This new target conveys her confidence in the biotech’s ability to climb 66% higher over the next year. (To watch Yang’s track record, click here)What does the rest of the Street have to say? As it turns out, when it comes to SELB, other analysts are also on board. With 5 Buy ratings assigned in the last three months compared to no Holds or Sells, the word on the Street is that the stock is a Strong Buy. Not to mention the $8.67 average price target puts the potential twelve-month gain at 105%. (See Selecta stock analysis on TipRanks) Ocular Therapeutix (OCUL)This biopharma uses a hydrogel platform to develop innovative treatments for various eye diseases. While its DEXTENZA insert has received FDA approval for the treatment of inflammation and pain following ophthalmic surgery, analysts point to its development pipeline as being capable of driving further growth on top of its already posted 57% one-year rise.On February 7, the company released data from the Phase 1 clinical trial for its OTX-TIC candidate at the Glaucoma 360 conference in San Francisco. The trial is studying the long acting travoprost intracameral implant’s ability to reduce intraocular pressure (IOP) in patients with primary open angle glaucoma or ocular hypertension.The data readout was a major positive for the company, as the candidate was not only able to lower IOP levels very fast, but it also sustained these reduced levels for significant periods of time, 18 months in one case. Adding to the good news, OTX-TIC was found to be well tolerated and safe, with no serious adverse events reported. It should also be noted that OCUL has kicked off the third and fourth cohort enrollment for the Phase 1 trial, and it will continue to monitor the first two cohorts long-term.This trial outcome has certainly impressed Wall Street analysts, namely Yi Chen of H.C. Wainwright. Thanks to the positive data announced so far, the five-star analyst argues that the candidate is more likely to receive approval from the FDA, increasing the pobability from 20% to 30%. To this end, Chen boosted the price target by $2 in addition to reiterating his Buy recommendation. At $8, the new target implies that shares could surge 42% over the next year. (To watch Chen’s track record, click here)Like the H.C. Wainwright analyst, Piper Sandler’s Joseph Catanzaro believes that the data was promising enough to warrant a price target increase. Along with his Overweight rating, the four-star analyst lifted the price target from $5.50 to $7. (To watch Catanzaro’s track record, click here)When looking at other analyst activity, it has been relatively quiet as only one other analyst has published a recent review. That being said, the call was also bullish, making the consensus rating a Strong Buy. Given the $7.33 average price target, a 30% twelve-month gain could be in the cards. (See Ocular Therapeutix stock analysis on TipRanks) Lithia Motors (LAD)Switching gears now, we move on to Lithia Motors, one of the largest car retailers in the U.S. While the name has taken some heat recently, several analysts still see more growth in store for the company, which has already posted a 46% twelve-month gain.In 2019, Lithia became the broadest coast-to-coast car retail network after it expanded its reach to include 92% of the U.S. Currently, the company’s physical network is comprised of 189 stores located across the U.S., with 21 brands of vehicles being represented in California alone.That being said, the auto retailer isn’t finished growing just yet. Last week, Lithia announced that it had acquired two Lexus stores in Sacramento and Roseville, California. According to statements from President and CEO Bryan DeBoer, these two locations could see revenue reach $160 million.Craig-Hallum analyst Ryan Sigdahl doesn’t dispute the fact that the temporary pressure on margins caused him to assume a lower premium to comps. He does remind investors, though, that overall, the company’s most recent quarter was solid. During the quarter, Lithia Motors was able to generate “strong” 7% year-over-year same-store sales growth in a slowing SAAR environment as a result of strength in its used vehicle business. Additionally, the analyst argues that the reason its profits took a hit was its integration of recent acquisitions and its efforts to position itself for a “banner year of growth”.In line with his optimistic approach, Sigdahl tells investors that the recent weakness presents an attractive entry-point. Along with his Buy rating, though, the analyst did reduce the price target from $200 to $170. However, the target still leaves room for a possible twelve-month gain of 31%. (To watch Sigdahl’s track record, click here)Looking at the consensus breakdown, it appears that other Wall Street pros are on the same page. As 100% of the analysts that have issued a recent recommendation see the stock as a Buy, the message is clear: LAD is a Strong Buy. On top of this, the $168 average price target suggests 30% upside potential. (See Lithia Motors stock analysis on TipRanks)

  • Loss-Making Ocular Therapeutix, Inc. (NASDAQ:OCUL) Expected To Breakeven
    Simply Wall St.

    Loss-Making Ocular Therapeutix, Inc. (NASDAQ:OCUL) Expected To Breakeven

    Ocular Therapeutix, Inc.'s (NASDAQ:OCUL): Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the...

  • Is Ocular Therapeutix, Inc. (NASDAQ:OCUL) Overpaying Its CEO?
    Simply Wall St.

    Is Ocular Therapeutix, Inc. (NASDAQ:OCUL) Overpaying Its CEO?

    Antony Mattessich has been the CEO of Ocular Therapeutix, Inc. (NASDAQ:OCUL) since 2017. This report will, first...

  • Did Hedge Funds Drop The Ball On Ocular Therapeutix Inc (OCUL) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Ocular Therapeutix Inc (OCUL) ?

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]

  • Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?
    Simply Wall St.

    Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Thomson Reuters StreetEvents

    Edited Transcript of OCUL earnings conference call or presentation 12-Nov-19 1:00pm GMT

    Q3 2019 Ocular Therapeutix Inc Earnings Call

  • Ocular Therapeutix (OCUL) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Ocular Therapeutix (OCUL) Reports Q3 Loss, Misses Revenue Estimates

    Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 2.17% and -23.59%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Moving Average Crossover Alert: Ocular Therapeutix
    Zacks

    Moving Average Crossover Alert: Ocular Therapeutix

    Ocular Therapeutix, Inc. (OCUL) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

  • American City Business Journals

    These 9 Massachusetts companies rank among the 'happiest' in the country

    Employees at some of Boston's biggest tech companies are among the happiest workers in the country, according to new data

  • Keep Your Eye on These 4 Healthcare Stocks
    Motley Fool

    Keep Your Eye on These 4 Healthcare Stocks

    The growing eye industry is something investors can’t ignore.

  • Thomson Reuters StreetEvents

    Edited Transcript of OCUL earnings conference call or presentation 7-Aug-19 8:30pm GMT

    Q2 2019 Ocular Therapeutix Inc Earnings Call

  • Read This Before Selling Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares
    Simply Wall St.

    Read This Before Selling Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates

    Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -35.71% and -35.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
    Zacks

    Allergan Announces FDA Acceptance of Glaucoma Candidate NDA

    The FDA accepts Allergan's (AGN) NDA seeking approval for Bimatoprost SR. A decision is expected in first half of 2020.

  • Implied Volatility Surging for Ocular (OCUL) Stock Options
    Zacks

    Implied Volatility Surging for Ocular (OCUL) Stock Options

    Investors need to pay close attention to Ocular (OCUL) stock based on the movements in the options market lately.

  • Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
    Zacks

    Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza

    Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.

  • Benzinga

    Bulls And Bears Of The Week: Tyson, Tesla, Crocs And More

    Benzinga examined prospects for many investor favorite stocks over the past week. U.S. stocks finished higher for a third straight week, including new highs for the Dow and the S&P 500, bolstered by mid-week signals from the Federal Reserve. While the Fed opted to hold steady on interest rates with a reiteration that the economy remains strong, it did intimate that it is open to an interest rate cut before the end of the year.